News 2017-09-13T16:17:27+00:00

NEWS 2016

moksha8 entered an exclusive distribution and marketing agreement in Mexico for VESANOID® a CHEPLAPHARM product

moksha8 and CHEPLAPHARM, a family owned pharmaceutical company based in Germany, have recently stepped up their relationship, signing a licensing deal that will see moksha8 take responsibility for the import, distribution, marketing and sale of VESANOID® in Mexico.

VESANOID® contains the ingredient Tretinoin and is applied in the treatment of a special form of leukemia, the Acute Promyelocytic Leukemia (APL) which is a subtype of the Acute Myeloid Leukemia (AML)

moksha8 Attains Brainsway Regulatory Approval for Marketing Deep TMS in Mexico

Brainsway Ltd. (TASE:BRIN), the leader in the development of advanced noninvasive treatments for brain disorders, announced that it has received local regulatory approval for the marketing and distribution of Brainsway Deep TMS (Transcranial Magnetic Stimulation) in Mexico. The company entered an exclusive distribution and marketing agreement with Moksha8, a leading specialty pharmaceutical company in Latin America, who has exclusive rights to distribute Deep TMS in Mexico.

“At least 15 million Mexicans suffer from a mental illness, many of whom do not have access to quality care,” said David Zacut, chief executive officer of Brainsway. “Our technology has been well-received globally, and we are confident that together with Moksha8 we will be able to provide hope to the people of Mexico.”

NEWS 2015

Brainsway joins Mexico through an exclusive distribution deal with moksha8


Brainsway LTD (TASE: BRIN), leader in non-invasive brain stimulation, is pleased to announce a new alliance with moksha8, a leading company in the marketing of medicines for the CNS in Latin America, for the exclusive distribution of Transcranial Magnetic Stimulation Deep in Mexico. Moksha8 intends to register and start the marketing of several Deep EMT devices in 2016 and has already committed to launch 10 devices in the next 12 months.


“Brainsway is excited to announce this new alliance. I am sure that with Brainsway technology and the presence of moksha8 in the Mexican market, we will have a great success opening a new horizon for Deep EMT technology. We hope to be able to make the treatment affordable for the majority of patients suffering from major depression in Mexico, who are desperately seeking new solutions. The agreement reflects Brainsway’s strategy to expand its facilities, “said Dr. Guy Ezekiel, President and CEO of Brainsway.


Mexico is a highly promising market for Brainsway Deep EMT, since no other EMT device has been approved in this country. Under this agreement, moksha8 will promote registration, medical education and in-sales activities related to Deep EMT in Mexico.


“We are excited to bring the Deep EMT to Mexico. It is a perfect complement to our portfolio of CNS drugs, since the need for an effective and non-invasive solution for patients with depression is enormous, “said Joel Barlan, CEO of moksha8. “Brainsway technology is an innovative solution eagerly awaited.”


About Brainsway


Braisnway is a leading company dedicated to the development of treatments for brain disorders. Brainsway Deep TMS (Transcranial Magnetic Stimulation) effectively treats non-invasive depression, avoiding side effects, and is effective for patients resistant to treatment of depression. Brainsway’s technology was approved by the FDA for the treatment of patients with depression who did not respond to several pharmacological treatments in the depressive episode. Brainsway Deep EMT was enthusiastically received by the international academic community, with 60 clinical trials in various institutions globally. For more information, please visit www.brainsway.com


About moksha8


Moksha8 is a significant pharmaceutical company in Latin America with a focus on marketing high quality drugs with the best operation and high adherence to the Foreign Corrupt Practices Act (FCPA). The company began its commercial operations in 2008 and currently has a sales force of 120 representatives in Brazil and Mexico, mainly promoting products for SNC.

NEWS 2014

Biopas and moksha8 Announce Strategic Alliance to Commercialize Specialty Pharmaceuticals Across Latin America

São Paulo, Brazil, Panamá City, Panamá, June 16, 2014 – Biopas and moksha8, two leading specialty pharmaceutical companies, announced today that they have entered into a strategic alliance combining strong capabilities, regional presence and product pipelines. The alliance immediately creates a unique regional provider of high quality, specialty pharmaceutical products across one of the world’s fastest growing, high value markets. Biopas and moksha8 will collaborate on both existing and future corporate development partnerships.

Both Biopas and moksha8 have strong existing partnerships with exclusive rights to high value products from companies including UCB, Ferring, Forest Laboratories, GSK, Sandoz and Ipsen. Among key brands are Viibryd, Cimzia, Dysport, Utrogestan, Queopine and Razapina. moksha8 has operations in Brazil and Mexico and Biopas has operations in the other key Latin America markets including Colombia, Venezuela, Argentina and Central America.

Biopas and moksha8 will initiate the alliance through commercialization of Viibryd (vilazodone HCL) as a regional, Latin America brand. Viibryd is the first of its kind antidepressant to receive approval from the FDA.
CEO of moksha8 and CEO of Biopas highlighted that “both companies share a common set of values and culture, which form a strong foundation to realize the full value of our products in Latin America and provide significant competitive advantages and differentiation”.

About moksha8

moksha8 is a leading Latin American pharmaceutical company, with a core focus on commercializing the highest quality medicines with best in class operations and strong FCPA compliance. The company launched its commercial operations in 2008 in Brazil and Mexico promoting primarily CNS products. moksha8 has a broad alliance with Forest Laboratories throughout Latin America and partnerships with GSK, Sandoz, Aurobindo and Accord in Brazil. The company was founded by Simba Gill and TPG Biotechnology. Major investors include TPG Biotechnology and Montreux Equity Partners. For additional information on moksha8, please visit the company’s web site at www.moksha8.com.

About Biopas

Established in 2002, Biopas is a leading Latin American pharmaceutical company with a particular focus on carving out strong market positions for exclusive products towards unmet critical patients’ needs. Biopas’ outstanding market access strategy and strict compliance policies allowed it to build long-standing commercial relationships with multiple leading international companies. Biopas operates in most of Latin America and commercializes a unique portfolio of lead products including CNS, cardiology, rheumatology, women’s health, gastroenterology and dermo-cosmetics products. Since 2002, Biopas achieved steady and outstanding annual revenue growth and products’ portfolio expansion. For additional information on Biopas, please visit the company’s web site at www.biopasgroup.com.

NEWS 2012

Forest Laboratories and moksha8 Form Broad Strategic Alliance for Latin America

New York and Sao Paulo, October 22, 2012 — Forest Laboratories, Inc. (NYSE: FRX), an international pharmaceutical company, and moksha8, a leader in the commercialization of CNS medicines in Latin America, today announced that they have entered into a broad strategic alliance that will provide Forest with a commercial footprint in Latin America and give moksha8 access to Viibryd® and potentially other Forest products for the Latin American market.
The alliance includes an exclusive license from Forest to moksha8 to commercialize Viibryd®, and potentially other Forest products, in Latin America. In addition, Forest will provide up to $125 million in financing to moksha8 in several tranches over a two-year period, conditioned upon moksha8 achieving certain business goals. At the conclusion of this two-year period, Forest will have the option to acquire moksha8 in a merger transaction. The moksha8 shareholders will also have a put option at such time, provided that moksha8 has achieved certain business objectives. In connection with the alliance, moksha8 has expanded its license arrangement with Watson Pharmaceuticals, Inc. (NYSE: WPI), to extend moksha8’s rights to commercialize a portfolio of Watson CNS branded generic products in Brazil and Mexico and has bought out Watson’s minority equity position in moksha8. Other financial terms were not disclosed.


David Solomon, Senior Vice President of Corporate Development and Strategic Planning of Forest Laboratories Inc. said, “We are pleased to enter into this transaction with moksha8, which provides Forest access in a risk controlled manner to a high quality commercial operation in Latin America, one of the largest and fastest growing pharmaceutical markets in the world. Moksha8 is uniquely positioned to commercialize novel products such as Viibryd® in Latin America, and Forest will augment the moksha8 pipeline through our broad global partner network and business development reach. This alliance will in time contribute important incremental profits and growth to Forest and is consistent with Forest’s strategy to improve returns on our product investments through fiscally responsible international expansion. We are also pleased with the agreement between moksha8 and Watson, as Watson’s high quality branded generic products are complementary to Viibryd® and the other novel brands Forest expects to provide to moksha8.”


Simba Gill, Chief Executive of moksha8 said “Forest has built one of the strongest proprietary drug pipelines in the industry and we are excited to partner with Forest to commercialize these products in the fast growth markets of Latin America. We are also very pleased to build on our successful partnership with Watson, which has one of the strongest branded generics portfolios in the industry and with whom we have rapidly become a market leader in the area of branded generic CNS medicines in Brazil.”
Fred Wilkinson, President Global Brands and Biosimilars of Watson said “We are pleased to be able to expand on our successful partnership with moksha8 in commercializing branded generic CNS products in Brazil and Mexico. We are also pleased with the alliance between moksha8 and Forest which will provide moksha8 with novel brands that are complementary to our branded generic CNS products.”
Today, the Latin America pharmaceutical market is USD $67 billion with a CAGR of over 14% over the last 5 years. Brazil ad Mexico account for two thirds of the Latin America market value. The CNS market in Latin America is estimated to be approximately USD $6 billion.

About Viibryd®
Viibryd® is a novel antidepressant for the treatment of major depressive disorder (MDD). The efficacy of Viibryd® was established in two 8-week, multi-center, randomized, double -blind, placebo-controlled studies in adult (18-80 years of age) outpatients who met the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) criteria for MDD. The mechanism of action of Viibryd is not fully understood but is thought to be related to enhancement of serotonergic activity in the central nervous system through selective inhibition of serotonin reuptake. Viibryd® is also a partial agonist of serotonergic 5-HT1a receptors; however, the net result of this action on serotonergic transmission and its role in Viibryd® antidepressant effect are unknown. Viibryd® is not yet approved in Brazil or Mexico and regulatory submission of Viibryd® in these countries is expected in Forest’s next fiscal year.
Forest will manufacture and supply Viibryd® to moksha8, under its license from Merck-Serono, and moksha8 will have exclusive rights to market, sell and distribute Viibryd® in Latin America.

About Forest Laboratories
Forest Laboratories’ (NYSE: FRX) longstanding global partnerships and track record developing and marketing pharmaceutical products in the United States have yielded its well-established central nervous system and cardiovascular franchises and innovations in anti-infective, respiratory, gastrointestinal and pain management medicine. Forest’s pipeline, the most robust in its history, includes product candidates in all stages of development across a wide range of therapeutic areas. The Company is headquartered in New York, NY. To learn more, visit www.FRX.com.


About moksha8
moksha8 is a significant Latin American pharmaceutical company, with a core focus on commercializing the highest quality medicines with best in class operations and strong FCPA compliance. The company launched its commercial operations in 2008 and currently deploys a field force of 120 representatives in Brazil and Mexico promoting primarily CNS products. moksha8 has a broad alliance with Forest Laboratories throughout Latin America and a partnership with Watson to commercialize certain Watson branded generic products in Brazil and Mexico. The company was founded by Simba Gill and TPG Biotechnology. Major investors include TPG Biotechnology and Montreux Equity Partners. For additional information on moksha8, please visit the company’s web site at www.moksha8.com.
Deutsche Bank is acting as financial advisor to moksha8.


Forward-Looking Statements
Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Forest’s, Watson’s and moksha8’s current perspective of existing information as of the date of this release. It is important to note that Forest, Watson and moksha8’s goals and expectations are not predictions of actual performance. Actual results may differ materially from Forest, Watson and moksha8’s current expectations depending upon a number of factors affecting Forest’s, Watson’s and moksha8’s business. These factors include, among others, the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and moksha8, their subsidiaries, and their third party manufacturers’ facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid and similar laws in non-U.S. jurisdictions, including Brazil and Mexico, affecting, among other things, pricing and reimbursement of pharmaceutical products; and other risks and uncertainties detailed in Watson’s periodic public filings with the Securities and Exchange Commission, including but not limited to Forest and Watson’s annual reports on Form 10-K for the year ended March 31, 2011 and December 31, 2011 and Forest and Watson’s quarterly reports on Form 10-Q for the period ended June 30, 2012. Except as expressly required by law, Forest, Watson and moksha8 disclaim any intent or obligation to update these forward-looking statements.

NEWS 2011

moksha8 and Watson Pharmaceuticals launch Kitapen® for schizophrenia and bipolar disease

Sao Paulo, Brazil, April 11, 2011 — Six months after establishing a partnership to commercialize high quality branded generics in Latin America, moksha8 and U.S. generics leader Watson Pharmaceuticals, have launched Kitapen®, the first and only branded generic of quetiapine available in the Brazilian market. The drug was approved by ANVISA for the treatment of schizophrenia and bipolar disorder.


The launch of Kitapen® strengthens moksha8’s leadership position in the commercialization of high quality CNS medicines in Latin America. “This partnership marks moksha8’s entry into the rapidly growing branded generics market and immediately strengthens our position as a leader in the treatment of CNS disorders, including depression, anxiety, bipolar and schizophrenia,” stated Dr. Simba Gill, moksha8’s CEO.


Kitapen® is classified as a branded generic product with demonstrated bioequivalence to the reference compound quetiapine and is more affordable for patients. Bioequivalence studies are designed to demonstrate that the generic product has the same efficacy, safety and quality as the reference product. Kitapen® is priced at approximately 50% of the price of the reference product and is manufactured in Canada where it is also approved and marketed for the treatment of schizophrenia and bipolar disorder.


“Drug therapy has a fundamental function in controlling both diseases and is crucial to restore quality of life of these patients. For most of them, this treatment, combined with psychosocial strategies, allows the reintegration into family, society and work,” says Dr. L. Alcioly T. Lacey, one of the founders of the Synapse Institute of Clinical Neurosciences. Several studies, for example, show that 50% of schizophrenic patients are hospitalized only once, and in 60% of these cases, with an appropriate treatment, they are able to achieve a social and professional reintegration.

In addition to Kitapen®, under its alliance with Watson, moksha8 currently commercializes Carbolim® (lithium) to treat bipolar disorder, Vicodil® (paracetamol and codeine) for moderate to severe pain and Fatig®, a multi-vitamin. Moksha8 is planning to launch three to four additional products in Brazil in 2011. These anticipated product launches will be high-quality affordable medicines to address significant mental health indications affecting a growing number of Brazilians, such as Alzheimer’s disease, bipolar disorder, schizophrenia and depression.

Schizophrenia and bipolar disorder affect over 2 million people in Brazil. Throughout the country, over 23 million people suffer from some kind of mental disorder. Providing safe effective medicines at an affordable price may help improve the lives of millions of people that would not otherwise be able to positively contribute to society.


Kitapen® (quetiapine) is part of a drug group known as atypical or second generation antipsychotics, which have a better tolerability (fewer side effects) compared to first-generation antipsychotics. Quetiapine is used to treat the symptoms of schizophrenia and is also used alone or with other medications to treat or prevent episodes of mania or depression in patients with bipolar disorder. Quetiapine works by changing the activity of certain natural substances in the brain.

About moksha8
Moksha8 is a leading pharmaceutical company in Latin America. The company is partnered with Roche, Pfizer, BioCryst and Watson in Brazil and Mexico. Moksha8 was founded in 2007 by Simba Gill and TPG Biotechnology. Major investors include TPG Biotechnology, Montreux Equity Partners and Watson Pharmaceuticals. For additional information on moksha8, please visit the company’s Website at www.moksha8.com.

Moksha8 commercializes 21 branded products in Latin America, focused on CNS, infectious disease and pain disorders. Together, Brazil and Mexico represents 75% of the $40 billion pharmaceutical market in Latin America. Moksha8 is the preferred and high quality partner of pharmaceutical and biotechnology companies, which seek to capture value in Latin America.

About Watson Pharmaceuticals, Inc.
Watson Pharmaceuticals, Inc. is the third largest generics company in the US and a leader in specialized branded pharmaceutical products focused on Urology and Women’s Health.

Watson was founded in 1984 and operates in approximately 20 countries world-wide. For press releases and other company information, please visit Watson Pharmaceuticals’ Web site at www.watson.com.

NEWS 2010

Watson, Moksha8 Form Marketing Partnership for Brazil, Mexico;

Morristown, NJ, and Sao Paulo, Brazil, October 4, 2010 – Watson Pharmaceuticals, Inc. (NYSE: WPI) and Moksha8, based in Sao Paulo, Brazil, today announced that they have entered into an agreement that will expand Watson’s commercial presence in Latin America’s two largest markets, Brazil and Mexico. 


“This unique partnership further demonstrates our commitment to expand our global footprint through creative business solutions that maximize the commercial opportunities for our current portfolio of brands and branded generics, establish the foundation for future growth in high value and expanding markets, and creates immediate value for both partners,” said Paul Bisaro, Watson’s President and Chief Executive Officer.


“The management team of Moksha8, led by Simba Gill, has a proven track record of effectively commercializing products within the brand and branded generic markets of Mexico and Brazil. This agreement, which provides Watson with an initial equity position, enables us to help fund Moksha8’s expansion and to share in their continued success. The partnership complements Watson’s existing commercial operations in Brazil, while establishing an expanded longer-term strategy to grow our presence in Brazil, establish our presence in Mexico and develop a pan- Latin American growth strategy,” Bisaro continued.


“The addition of Watson to our current business expands our existing portfolio and pipeline of high quality products for the Latin America market,”” said Simba Gill, Chief Executive Officer of Moksha8. “Further, this partnership marks moksha8’s entry into the rapidly growing branded generics market and immediately strengthens our position as a leader in the treatment of CNS disorders including depression, anxiety and schizophrenia.”


Watson will manufacture and supply select products to Moksha8, which will have exclusive rights to market, sell and distribute these products in Brazil and Mexico. Moksha8 and Watson have initially identified approximately one dozen product candidates, with the opportunity to expand the commercialization and marketing agreement to include additional products in the future.
Watson will continue to own all marketing authorizations, and Moksha8 will be responsible for sales, marketing and commercialization expenses.


Moksha8 currently markets 21 branded products for third parties in Latin America, utilizing a field force of approximately 180 sales representatives in the areas of CNS, infectious disease and pain. Combined, Brazil and Mexico make up 75% of the $40 billion USD Pharmaceutical market in Latin America. Moksha8 is the high quality partner of choice for pharmaceutical and biotechnology companies seeking to capture value in Latin America.


Watson currently manufactures and markets select generic products in the Brazilian marketplace through a Brazilian subsidiary. This venture will have no impact on that subsidiary’s current operations, including current management, manufacturing and supply chain; Moksha8 will complement Watson’s Brazilian sales and marketing capabilities.


About Moksha8
Moksha8 is a leading pharmaceutical company in Latin America. The company is partnered with Roche, Pfizer, BioCryst and Watson in Brazil and Mexico. Moksha8 was founded in 2007 by Simba Gill and TPG Biotechnology. Major investors include TPG Biotechnology and Montreux Equity Partners. For additional information on Moksha8, please visit the company’s Web site at www.moksha8.com.


About Watson Pharmaceuticals, Inc.
Watson Pharmaceuticals, Inc. is a leading global specialty pharmaceutical company. The company is engaged in the development and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women’s Health. Watson has operations in many of the world’s established and growing international markets.
For press releases and other company information, please visit Watson Pharmaceuticals’ Web site at www.watson.com


Forward-Looking Statements
Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson’s and Moksha8’s current perspective of existing information as of the date of this release. It is important to note that Watson’s and Moksha8’s goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson’s and Moksha8’s current expectations depending upon a number of factors affecting Watson’s and Moksha8’s business. These factors include, among others, the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and Moksha8, their subsidiaries, and their third party manufacturers’ facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid and similar laws in non-U.S. jurisdictions, including Brazil and Mexico, affecting, among other things, pricing and reimbursement of pharmaceutical products; and other risks and uncertainties detailed in Watson’s periodic public filings with the Securities and Exchange Commission, including but not limited to Watson’s annual report on Form 10-K for the year ended December 31, 2009 and Watson’s quarterly report on Form 10-Q for the period ended June 30, 2010. Except as expressly required by law, Watson and Moksha8 disclaim any intent or obligation to update these forward-looking statements.

 

 
moksha8 and BioCryst Gain Approval for the Importation and Use of Peramivir in Mexico for the Treatment of H1N1 Influenza
– moksha8 also announces $25M financing led by Montreux Equity Partners –


MEXICO CITY and BIRMINGHAM, Ala., Jan. 12 /PRNewswire-FirstCall/ — moksha8 and BioCryst today announced that moksha8 has been granted approval from COFEPRIS (The Federal Commission for the Protection against Sanitary Risk) in Mexico for the importation and use of peramivir in patients with influenza associated with the 2009 H1N1 influenza A strain. moksha8 has also filed for regulatory approval of peramivir in Brazil. Peramivir is the only intravenous (i.v.) antiviral that is currently available under an Emergency Use Authorization in the U.S. in certain adult and pediatric patients with confirmed or suspected 2009 H1N1 influenza A infection who are admitted to a hospital.
“Rapidly bringing important novel products to patients in need in Mexico and Brazil is core to our vision,” said Ayse Kocak, Head of moksha8 in Mexico. “The rapid approval of peramivir for importation and use is a strong validation of the Mexican Government’s commitment to public health. We look forward to bringing this potentially life saving drug to as many patients as possible.”
“We are pleased that the Mexican government has authorized the use of peramivir to treat its citizens who are infected with 2009 H1N1 influenza A,” said Jon P. Stonehouse, President and Chief Executive Officer of BioCryst Pharmaceuticals. “The relationship between BioCryst and moksha8, established only three months ago, is producing the near-term results we desired. We are prepared to respond to any peramivir order we may receive under this authorization from Mexico.”
“Peramivir is an important part of our influenza preparedness program,” said Miguel Angel Toscana, Federal Commissioner of COFEPRIS (Mexico’s Federal Commission for the Protection against Sanitary Risk). “Approval of peramivir importation will help our mission of protecting our nation.”
The 2009 H1N1 influenza A virus is a new influenza virus and one to which most people have no or little immunity and, therefore, this virus could cause more infections than are seen with seasonal flu. The severity of the disease ranges from very mild symptoms to severe illnesses that can result in death.
In September 2009, moksha8 signed a binding letter of intent to exclusively represent BioCryst and its anti-viral peramivir for influenza stockpiling opportunities, as well as for marketing and distribution of peramivir for seasonal influenza upon local regulatory approval, in certain Latin American countries, including Brazil and Mexico.
moksha8 also announced that it has raised $25 million in a Series C financing led by Montreux Equity Partners. Existing investor TPG Biotechnology and CEO, Simba Gill, also participated in the financing.
moksha8 has established broad commercial operations in Mexico and Brazil, the two largest pharmaceutical markets in Latin America. Together they represent 75% of a $30 billion market in Latin America. The Company is currently commercializing approximately $200 million of products in the infections disease, central nervous system and inflammation therapeutic areas under partnerships with Roche and Pfizer. Products in the Company’s portfolio include key brands such as Rocephin®, Bactrim®, Lexotan®, Rivotril® as well as UnaSyn® and Vibramycin®.


About Peramivir
Peramivir is an anti-viral agent that inhibits the interactions of influenza neuraminidase, an enzyme which is critical to the spread of influenza within a host. In laboratory tests, peramivir has shown activity against pandemic H1N1 swine flu origin viral strains. Peramivir has been studied in over 1800 patients with complicated and uncomplicated influenza. In November 2009, Shionogi & Co., Ltd. filed for regulatory approval in Japan.


About moksha8
moksha8 was founded in December 2006 by Simba Gill and TPG Biotechnology, and has raised significant financing from top-tier private equity and venture capital firms, including TPG Biotechnology, Montreux Equity Partners and Votorantim Novos Negocios, the venture capital and private equity arm of Votorantim, one of Brazil’s largest privately held conglomerates. moksha8 is uniquely positioned as the partner of choice for both pharmaceutical and biotechnology companies seeking to capture value from their products in high growth emerging markets. moksha8 has established commercial operations in key geographies in Latin America including Sao Paulo and Mexico City. moksha8 provides the highest quality medicines to the fastest growing markets of the world.


About BioCryst
BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer and inflammatory diseases. BioCryst has progressed two novel compounds into late-stage pivotal clinical trials; peramivir, an anti-viral for influenza, and forodesine, a purine nucleoside phosphorylase (PNP) inhibitor for cutaneous T-cell lymphoma (CTCL). Utilizing crystallography and structure-based drug design, BioCryst continues to discover additional compounds and to progress others through pre-clinical and early development to address the unmet medical needs of patients and physicians. For more information, please visit the Company’s Web site at www.biocryst.com.

NEWS 2009

moksha8 Expands Alliance with Roche to Commercialize $200 Million of Products in Brazil and Mexico

Mexico City, Sao Paulo, Philadelphia, – May 20, 2009 /PR Newswire
moksha8, Inc. announced today that it has expanded its strategic partnership with Roche to commercialize an additional portfolio of products in Mexico currently generating sales of $140 million USD.
moksha8 will commercialize products in three therapeutic areas, CNS disease, anti-infectives, and inflammation. The product portfolio consists of well-known brands including Rivotril®, Rocephin® and Bactrim®
“moksha8 has produced strong results for Roche in Brazil and we are delighted to expand our relationship to include Mexico as a key country in Latin America” said Ernest Egli, President of Roche Latin America. “moksha8 brings strong commercial capabilities and innovative marketing to our CNS, anti-infectives and inflammation franchises. We look forward to continuing this valuable relationship.”

“moksha8 has established a broad footprint in Latin America with leading products that are cornerstones of medical care,”” said Simba Gill, CEO of moksha8. “We look forward to continuing our strong relationship with Roche and driving value from this important portfolio of products. We are now firmly positioned as the leading partner of choice for pharmaceutical and biotechnology companies looking to generate value across Latin America.”
In just over a year, moksha8 has grown its commercial organization to over 200 employees in Brazil and Mexico and a portfolio of products with sales of $200 million USD. moksha8 is uniquely positioned as the leading specialty pharmaceutical company in Latin America with a strong presence in CNS, anti-infectives and inflammation.
moksha8 was founded in December 2006 by Simba Gill and Texas Pacific Group, and has raised significant financing from top-tier private equity firms, including Texas Pacific Group and Votorantim Novos Negocios, the venture capital and private equity arm of Votorantim, one of Brazil’s largest privately held conglomerates. moksha8 is uniquely positioned as the partner of choice for both pharmaceutical and biotechnology companies seeking to capture value from their products in high growth emerging markets. moksha8 has established commercial operations in key geographies in Latin America including Sao Paulo and Mexico City, with corporate offices in Pennsylvania. moksha8 provides the highest quality medicines to the fastest growing markets of the world.

NEWS 2009

Moksha8 Launches Broad Product Portfolio in Key Emerging Markets
– Strategic Alliances with Roche and Pfizer Provide Portfolio of Over 20 Products –

Hong Kong, Sao Paulo, Shanghai, Philadelphia, PA –April 16, 2008 /PR Newswire
moksha8, Inc. announced today strategic partnerships with Roche and Pfizer, the launch of over twenty products and establishment of its Latin America headquarters in Sao Paulo, Brazil. moksha8 is committed to providing the highest quality medicine to the fastest growing markets of the world, with an initial focus on Asia, Latin America and Eastern Europe.


In February 2008, moksha8 established strategic alliances with Roche and Pfizer in four therapeutic areas, CNS disease, anti-infectives, cardiovascular disease and pain management. The initial Roche and Pfizer portfolios consist of more than 20 products, including Neurontin®, Lexotan®, Zoloft®, and Bactrim®


Moksha8 has established its Latin American headquarters in Sao Paulo, Brazil and has built a fully integrated sales and marketing team to drive the launch and commercialization of this comprehensive first line of products. Current annual sales of these products in Brazil are estimated to be over $80 million USD.


Moksha8 was founded in December 2006 by Simba Gill and TPG and has raised significant financing from top-tier private equity firms, including TPG and Votorantim Novos Negocios, the venture capital and private equity arm of Votorantim, one of Brazil’s largest privately held conglomerates. Moksha8 is uniquely positioned as the partner of choice for both pharmaceutical and biotechnology companies seeking to capture value from their products in high growth emerging markets. Moksha8 has established commercial operations in key geographies in Asia and Latin America with Corporate offices in Hong Kong and Philadelphia.


Moksha8 provides the highest quality medicines to the fastest growing markets of the world.